BioSpace News Archive

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, has bolstered its leadership team with the hire of Tim McDaniel as VP of Tech Development, and recent hires of Monique Cadle as VP of People, and Tobias Mann as VP of Software Engineering.

INOVIO today announced the signing of a non-binding memorandum of understanding (MOU) with Colombia’s Ministry of Health and Social Protection reflecting the intent to advance efforts to combat the pandemic and endemic threat posed by COVID-19 and to better prepare for future public health emergencies.

iSpecimen Inc. today announced that it will report its financial results for the third quarter ended September 30, 2021 , before the market open on Thursday, November 4, 2021 .

Dynavax Technologies Corporation will report third quarter 2021 financial results on Thursday, November 4, 2021, after the U.S. financial markets close.

A new study using genetic data of hundreds of thousands of people suggests that daily coffee and caffeine consumption can prevent kidney stones.

Harmony Biosciences Holdings, Inc. today announced that it will be added to the S&P SmallCap 600 ® Index, effective prior to the open of trading on Friday, October 22, 2021.

Graphite Bio, Inc. announced today that members of the management team will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Thursday, Oct. 28, 2021, at 4:30 p.m. ET.

Teva Pharmaceuticals today announced 25 presentations examining new Phase 3 clinical data, post hoc analyses and open-label extension (OLE) studies for both TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) and AUSTEDO® (deutetrabenazine) tablets.

Imvax, Inc. today announced a poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.

Cedilla Therapeutics today revealed its two lead conditional inhibitor programs: an inhibitor of TEAD for the treatment of solid tumors, such as mesothelioma and certain squamous cell carcinomas; and a highly selective inhibitor of CDK2 for the treatment of multiple tumor types, including CDK4/6-resistant breast cancer, ovarian, uterine, stomach, and esophageal cancers.